Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 6, 1999, Pages 397-408

  Jardine, Alan ^a,c   Holdaas, H ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; MYOPATHY; MYOSITIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SURVIVAL TIME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; CYCLOSPORINE; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; KIDNEY TRANSPLANTATION;

EID: 0033392760     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00252.x     Document Type: Review

References (90)

1. 1. Stiller CR, for the Canadian Multicenter Transplant Study Group. (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. New England Journal of Medicine, 309, 809-816.
2. 2. Sutherland DER, Fryd DS, Strand MH, et al. (1985) Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. American Journal of Kidney Disease, V, 318-327.
3. 3. Brunner FP, Broyer M, Brynger H, et al. (1988) Survival on renal replacement therapy: data from the EDTA registry. Nephrology, Dialysis, Transplantation, 2, 109-122.
4. 4. Raine AE, Margreiter R, Brunner FP, et al. (1992) Report on management of renal failure in Europe, XXII, 1991. Nephrology, Dialysis, Transplantation, 7(Suppl. 2), 7-35.
5. 5. Aakhus S, Dahl K, Widerøe TE. (1999) Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology, Dialysis, Transplantation, 14, 648-654.
6. 6. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. (1991) Causes of renal allograft loss: progress in the 1980s, challenge for the 1990s. Annals of Surgery, 214, 679-688.
7. 7. Neaton JD, Wentworth DF. (1992) Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Archives of Internal Medicine, 152, 56-64.
8. 8. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. (1990) The prevalence of hyperlipidemia in renal transplant recipients. Transplantation, 50, 987-992.
9. 9. Appel GA. (1991) Lipid abnormalities in renal disease. Kidney International, 39, 169-183.
10. 10. Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. (1991) Atherosclerosis and lipid disorders after renal transplantation. Kidney International, 39(Suppl. 31), S24-S28.
11. 11. Dimény E, Wahlberg J, Lithell H, Fellström B. (1995) Hyperlipidaemia in renal transplantation - risk factor for long-term graft outcome. European Journal of Clinical Investigations, 25, 574-583.
12. 12. Vathsala A, Weinberg RB, Schoenberg L, et al. (1989) Lipid abnormalities in cyclosporine-prednisolone-treated renal transplant recipients. Transplantation, 48, 37-43.
13. 13. Coresh R, Longenecker C, Miller ER, Young HJ, Klag MJ. (1998) Epidemiology of cardiovascular risk factors in chronic renal disease. Journal of the American Society of Nephrology, 9, S24-S30.
14. 14. Kasiske BL, Umen AJ. (1987) Persistent hyperlipidemia in renal transplant patients. Medicine, 66, 309-316.
15. 15. Arnadottir M, Berg A-L. (1997) Treatment of hyperlipidemia in renal transplant recipients. Transplantation, 63, 339-345.
16. 16. Harris KPG, Russell GI, Parvin SD, Veitch PS, Walls J. (1986) Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. British Medical Journal, 292, 16.
17. 17. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV. (1991) The adverse impact of cyclosporine on serum lipids in renal transplant recipients. American Journal of Kidney Diseases, 17, 700-707.
18. 18. Kuster GM, Drexel H, Bleisch JA, et al. (1994) Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation, 57, 1479-1483.
19. 19. Callard P, Bedrossian J, Idatte JM, et al. (1975) The arterial lesions in the cause of renal allograft rejection. Advances in Nephrology, 5, 333-353.
20. 20. Woo YM, Jardine AG, Clark AF, et al. (1999) Early graft function and patient survival following cadaveric renal transplantation. Kidney International, 55, 692-699.
21. 21. Tonstad S, Holdaas H, Goørbitz C, Ose L. (1995) Is dietary intervention effective in post-transplant hyperlipidemia? Nephrology, Dialysis, Transplantation, 10, 82-85.
22. 22. Keogh A, Day R, Critchley L, Duggin G, Baron D. (1988) The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proceedings, 20, 27-30.
23. 23. Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G. (1995) Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labelled crossover trial. American Journal of Kidney Diseases, 25, 616-622.
24. 24. Bradford RH, Shear CL, Chremos AN, et al. (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine, 151, 43-49.
25. 25. Farmer JA, Washington LC, Jones PH, Shapiro DR, Goto AM, Mantell G. (1992) Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clinical Therapy, 14, 708-717.
26. 26. Lambrecht LF, Malini PL. (1993) Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group. Acta Cardiologica, 48, 541-554.
27. 27. Lovastatin/Pravastatin Study Group. (1993) A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. American Journal of Cardiology, 71, 810-815.
28. 28. Peters TK, Muratti EN, Mehra M. (1994) Fluvastatin in primary hypercholesterolemia. efficacy and safety in patients at high risk. An analysis of a clinical trial database. American Journal of Medicine, 96(Suppl. 6A), 79S-83S.
29. 29. Steinhagen-Thiessen E, on behalf of the Simvastatin Pravastatin European Study Group. (1994) Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology, 85, 244-254.
30. 30. Herd JA, Ballantyne CM, Farmer JA, et al. (1997) Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). American Journal of Cardiology, 80, 278-286.
31. 31. Schuster H, Berger J, Luft FC. (1998) Randomised, doubleblind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. British Journal of Cardiology, 5, 597-602.
32. 32. Beil S, Pfafferott C, Weber M, on behalf of the fluvastatin investigators. (1997) Fluvastatin lipid-lowering effect in routine practice conditions (FLIRT). Results of a drug surveillance study. Clinical Drug Investigations, 14, 146-153.
33. 33. Földes K, Makláry E, Vargha P, et al. (1998) Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow up. Transplant International, 11(Suppl. 1), S65-S68.
34. 34. Li PKT, Mak TWL, Chan TH, Wang A, Lam CWK, Lai KN. (1995) Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation, 60, 652-656.
35. 35. Holdaas H, Hartmann A, Stenstroøm J, Dahl K, Borge M, Pfister P. (1995) Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. American Journal of Cardiology, 76, 102A-106A.
36. 36. Schrama YC, Hené RJ, de Jonge N, et al. (1998) Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients, an exercise provocation test. Transplantation, 66, 1175-1181.
37. 37. Holdaas H, Hartmann A, Stenstroøm J, Nordal K, Berg K, Fauchald P. (1996) Effect of incremental doses of fluvastatin in renal recipients treated with cyclosporin [abstract]. 66th Congress of the European Atherosclerosis Society, 13-17 July. Florence, Italy.
38. 38. Plosker GL, Wagstaff AJ, Fluvastatin. (1996) A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs, 51, 433-459.
39. 39. Langtry HD, Markham A, Fluvastatin. (1999) A review of its use in lipid disorders. Drugs, in press.
40. 40. Austen JL, Shifrin FA, Bartucci MR, Knauss TC, Schulak JA, Hricik DE. (1996) Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Annals of Pharmacotherapy, 30, 1386-1389.
41. 41. Olbricht C, Wanner C, Eisenhauer T, et al. (1997) Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clinical Pharmacology and Therapeutics, 62, 311-321.
42. 42. Tobert JA. (1998) Efficacy and long-term adverse effects pattern of lovastatin. American Journal of Cardiology, 62, 28J-34J.
43. 43. Corpier CL, Jones PH, Suki WN, et al. (1988) Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. Journal of the American Medical Association, 260, 239-241.
44. 44. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. (1988) Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. New England Journal of Medicine, 318, 47-48.
45. 45. Norman DJ, Illingworth DR, Munson J, Hosenpud J. (1988) Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. New England Journal of Medicine, 318, 46-47.
46. 46. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. (1993) Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron, 65, 410-413.
47. 47. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. (1995) Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of hepatic cytochrome P450 enzyme system activity. Schweizerische Medizinische Wochenschrift, 125, 1342-1346.
48. 48. Keogh AM, Macdonal PS, Aboyoun C, Mundy JA, McCaffrey D, Spratt PM. (1999) Pravastatin confers superior survival after cardiac transplantation when compared to simvastatin [abstract]. Journal of the American College of Cardiology, 33, Abstract no. 855-2.
49. 49. Muck W. (1998) Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs, 56(Suppl. 1), 15-23.
50. 50. Hsu I, Spinler SA, Johnson NE. (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Annals of Pharmacotherapy, 29, 743-759.
51. 51. Smith PF, Eydelloth RS, Grossman SJ, et al. (1991) HMG-CoA. reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. Journal of Pharmacological and Experimental Therapy, 257, 1225-1235.
52. 52. Regazzi MB, Iacona I, Campana C, et al. (1993) Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proceedings, 25, 2732-2734.
53. 53. Kronbach T, Fischer V, Meyer UA. (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630-635.
54. 54. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450, 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Archives of Biochemistry and Biophysics, 290, 355-361.
55. 55. Prueksaritanont T, Gorham LM, Ma B, et al. (1997) In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drugs on hepatic P450s. Drug Metabolism and Disposition, 25, 1191-1199.
56. 56. Boberg M, Angerbauer R, Fey P, et al. (1997) Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metabolism and Disposition, 25, 321-331.
57. 57. Christians U, Jacobsen W, Floren LC. (1998) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacological Therapy, 80, 1-34.
58. 58. Dimitroulakos J, Yeger H. (1996) HMG-CoA. reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-lycoprotein expressing cells. Nature Medicine, 2, 326-333.
59. 59. Kitazawa E, Tamura N, Iwabuchi H, et al. (1993) Biotransformation of pravastatin sodium. Biochemistry and Biophysics Research Communications, 192, 597-602.
60. 60. Lindahl A, Sanström R, Ungell A-L, Lennernäs H. (1998) Concentration-and region-dependent intestinal permeability of fluvastatin the rat. Journal of Pharmacy and Pharmacology, 50, 737-744.
61. 61. Fischer V, Johanson L, Heitz F, et al. (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition, 27, 410-416.
62. 62. Appel S, Dingemanse J. (1996) Pharmacokinetics and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Review of Contemporary Pharmacotherapy, 7, 167-182.
63. 63. Goldberg R, Roth D. (1996) Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation, 62, 1559-1564.
64. 64. Hadjigavriel M, Kyriakides G. (1997) Fluvastatin in renal transplantation. Transplant Proceedings, 29, 3050.
65. 65. Locsey L, Asztalos L, Kincses Z, Balázs G. (1997) Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. International Urology and Nephrology, 29, 95-106.
66. 66. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
67. 67. Shepherd J, Cobbe SM, Ford I, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine, 333, 1301-1307.
68. 68. Sacks FM, Pfeffer MA, Moye LA, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine, 335, 1001-1009.
69. 69. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/ TexCAPS Research Group. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/ TexCAPS. Journal of the American Medical Association, 279, 1615-1621.
70. 70. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357.
71. 71. Serruys PW, Foley DP, Jackson G, et al. on behalf of the FLARE study group. (1999) A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. European Heart Journal, 20, 58-69.
72. 72. Bumgardner GL, Wilson GA, Tso PL, et al. (1995) Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation, 60, 1418-1421.
73. 73. Pollock CA, Mahony JF, Ong CS, Caterson RJ, Waught DA, Ibels S. (1995) Hyperlipidemia in renal transplant patients: does it matter and can we treat it? Transplant Proceedings, 27, 2152-2153.
74. 74. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. (1996) Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology, 7, 158-165.
75. 75. Aker S, Ivens K, Guo Z, Grabensee B, Heering P. (1998) Cardiovascular complications after renal transplantation. Transplant Proceedings, 30, 2039-2042.
76. 76. Hillebrand GF, Schlosser S, Schneeberger H, et al. (1999) No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Transplant Proceedings, 31, 1391-1392.
77. 77. Kobashigawa JA, Katznelson S, Laks H, et al. (1995) Effect of pravastatin on outcomes after cardiac transplantation. New England Journal of Medicine, 333, 621-627.
78. 78. Wenke K, MeiSeries B, Thiery J, et al. (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation, a four-year randomized trial. Circulation, 96, 1398-1402.
79. 79. Eich D, Thompson JA, Ko DJ, et al. (1991) Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary heart disease. Journal of Heart and Lung Transplantation, 10, 45-49.
80. 80. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. (1996) The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation, 61, 1469-1474.
81. 81. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. (1997) Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. British Journal of Clinical Pharmacology, 44, 537-542.
82. 82. Kobashigawa JA. (1996) Drugs in cardiac transplantation [letter]. New England Journal of Medicine, 334, 401-402.
83. 83. Hebert PR, Gaziano JM, Chan KS, Hennekens C.H. (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Journal of the American Medical Association, 278, 313-321.
84. 84. Katznelson W, Wang XM, Chia D, et al. (1998) The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. Journal of Heart and Lung Transplantation, 17, 335-240.
85. 85. Cutts JL, Bankhurst AD. (1990) Reversal of lovastatin-mediated inhibition of natural killer cell activity. Journal of Cell Physiology, 145, 244-252.
86. 86. Rothe G, Elbracht R, Hauser I, et al. (1997) Relative decrease of cytotoxic T cells in kidney transplanted patients [abstract]. Atherosclerosis, 134, 282.
87. 87. Arnadottir M, Eriksson L-O, Germershausen JI, Thysell H. (1994) Low-dose simvastatin is a well tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients, double-blind, randomized, placebo-controlled study in 40 patients. Nephron, 68, 57-62.
88. 88. Rosenson RS, Tangney CC. (1998) Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. Journal of the American Medical Association, 279, 1643-1650.
89. 89. Lal SM, Gupta N, Georgiev O, Ross G. (1997) Lipid-lowering of fluvastatin in renal transplant patients. A clinical observation. International Journal of Artificial Organs, 20, 18-21.
90. 90. Melchor JL, Gracida C. (1998) Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients. Transplant Proceedings, 30, 2054.